When analysed according to baseline CNS metastases status, CIR trends observed for CNS PD vs non-CNS PD in ALEX were similar to those in the pooled analysis described above, reinforcing the CNS effectiveness of alectinib in preventing or delaying CNS metastases in ALK-positive NSCLC (Gadgeel et al, 2017). This evidence concerns the gene ALK and non-small cell lung carcinoma.